These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 18380362)

  • 1. [Low prescription rates of generic lamotrigine and gabapentine].
    Mattsson P; Lindqvist T
    Lakartidningen; 2008 Feb 6-12; 105(6):385. PubMed ID: 18380362
    [No Abstract]   [Full Text] [Related]  

  • 2. The economic consequences of generic substitution for antiepileptic drugs in a public payer setting: the case of lamotrigine.
    Duh MS; Andermann F; Paradis PE; Weiner J; Manjunath R; Crémieux PY
    Dis Manag; 2007 Aug; 10(4):216-25. PubMed ID: 17718660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costing of antiepileptic drugs.
    Kochen S
    Lancet; 1996 Jan; 347(8996):266. PubMed ID: 8551913
    [No Abstract]   [Full Text] [Related]  

  • 4. If comparisons can be odious, so can assumptions.
    Jackson D; Duthie T
    Seizure; 1996 Sep; 5(3):247-8. PubMed ID: 8902930
    [No Abstract]   [Full Text] [Related]  

  • 5. [Clinical characteristics and treatment for new onset epilepsy in the elderly].
    Akamatsu N
    Rinsho Shinkeigaku; 2010 Nov; 50(11):895. PubMed ID: 21921498
    [No Abstract]   [Full Text] [Related]  

  • 6. Prescription drug trend begins showing modest slowdown.
    Capitation Rates Data; 2002 Jul; 7(7):76-80. PubMed ID: 12164063
    [No Abstract]   [Full Text] [Related]  

  • 7. [Antiepileptic treatment nearly six times more expensive since 1990].
    Persson PM; Russom A; Tomson T
    Lakartidningen; 2003 Jan; 100(1-2):42-6. PubMed ID: 12572136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cost minimization study comparing vigabatrin, lamotrigine and gabapentin for the treatment of intractable partial epilepsy.
    Hughes D; Cockerell OC
    Seizure; 1996 Jun; 5(2):89-95. PubMed ID: 8795122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intended and unintended consequences of the gabapentin off-label marketing lawsuit among patients with bipolar disorder.
    Chace MJ; Zhang F; Fullerton CA; Huskamp HA; Gilden D; Soumerai SB
    J Clin Psychiatry; 2012 Nov; 73(11):1388-94. PubMed ID: 23146199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The new anti-epileptic drugs.
    Murphy R
    Ir Med J; 1995; 88(6):198-9. PubMed ID: 8575915
    [No Abstract]   [Full Text] [Related]  

  • 11. [Just the costs which spin?].
    Palmetun-Ekback M; Lööf L; Eriksson I; Welander G; Eriksson AB; Back S; Stjerna A
    Lakartidningen; 2010 Mar 17-23; 107(11):774. PubMed ID: 20402274
    [No Abstract]   [Full Text] [Related]  

  • 12. Economic impact of generic substitution of lamotrigine: projected costs in the US using findings in a Canadian setting.
    LeLorier J; Duh MS; Paradis PE; Latrémouille-Viau D; Lefebvre P; Manjunath R; Sheehy O
    Curr Med Res Opin; 2008 Apr; 24(4):1069-81. PubMed ID: 18315941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of copayments and generic substitution on the use and costs of prescription drugs.
    Smith DG
    Inquiry; 1993; 30(2):189-98. PubMed ID: 8314607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact on health outcomes and healthcare utilisation of switching to generic medicines consequent to reference pricing: the case of lamotrigine in New Zealand.
    Lessing C; Ashton T; Davis P
    Appl Health Econ Health Policy; 2014 Oct; 12(5):537-46. PubMed ID: 25005492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical consequences of generic substitution of lamotrigine for patients with epilepsy.
    LeLorier J; Duh MS; Paradis PE; Lefebvre P; Weiner J; Manjunath R; Sheehy O
    Neurology; 2008 May; 70(22 Pt 2):2179-86. PubMed ID: 18505997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The risks and costs of multiple-generic substitution of topiramate.
    Duh MS; Paradis PE; Latrémouille-Viau D; Greenberg PE; Lee SP; Durkin MB; Wan GJ; Rupnow MF; LeLorier J
    Neurology; 2009 Jun; 72(24):2122-9. PubMed ID: 19528520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of pregabalin and gabapentin in palliative care #289.
    Pruskowski J; Arnold RM
    J Palliat Med; 2015 Apr; 18(4):386-7. PubMed ID: 25714108
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost-effectiveness model of adjunctive lamotrigine for the treatment of epilepsy.
    Heaney DC; Sander JW
    Neurology; 1999 Aug; 53(3):657-8. PubMed ID: 10449148
    [No Abstract]   [Full Text] [Related]  

  • 19. Newer anticonvulsants: lamotrigine, topiramate and gabapentin.
    Holmes LB; Hernandez-Diaz S
    Birth Defects Res A Clin Mol Teratol; 2012 Aug; 94(8):599-606. PubMed ID: 22730257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes.
    Andermann F; Duh MS; Gosselin A; Paradis PE
    Epilepsia; 2007 Mar; 48(3):464-9. PubMed ID: 17346246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.